Daily Newsletter

04 December 2023

Daily Newsletter

04 December 2023

SCARS Center selects SciBase’s Nevisense system to detect skin cancer

Nevisense helps to detect the most complex type of skin cancer at point-of-care.

RanjithKumar Dharma December 04 2023

The Skin and Cancer Reconstructive Surgery Center (SCARS Center) in California, US, has selected SciBase Holding’s Nevisense system for the detection of skin cancer early.

This collaboration aims to expand the presence of Nevisense in the wider US market.

Nevisense is claimed to be the first-of-its-kind artificial intelligence (AI)-driven technology designed to specifically address the challenges associated with detecting the most complex type of skin cancer at point-of-care.

It offers clinicians advanced analysis of irregular moles during routine skin examinations.

Nevisense is said to be the only device approved by the US Food and Drug Administration (FDA) to detect melanoma, and is also the only technology approved by the European Medical Device Regulation to detect skin cancer in Europe.

Skin Cancer and Reconstructive Surgery Center founder and medical director Dr Simon Madorsky said: “Through our new partnership with Nevisense, we are now one of the first groups in the country to adopt AI technology that will help our clinicians improve patient outcomes.”

SciBase has developed a unique point-of-care platform to non-invasively detect skin cancer and other skin conditions.

It offers Nevisense and Nevisense Go products for detecting melanoma and non-melanoma skin cancer, as well as assessing skin barrier function.

SciBase CEO Pia Renaudin said: “SciBase and the SCARS Center team are well aligned with a shared mission to provide clinicians with early detection of melanoma solutions that can drive improved patient outcomes.

“We are continuing to broaden SciBase's presence throughout the US, to further increase patient access to point-of-care technology that enables the earliest detection possible of melanoma when it is almost 100% curable.”

Why are healthcare companies hesitant to invest in the metaverse?

Although metaverse technologies could reinvent healthcare approaches and bring new experiences to healthcare providers and patients, adoption is still at an early stage. There are currently few use cases in the healthcare industry. The metaverse needs to overcome major challenges for healthcare, including regulation and data privacy concerns.

Healthcare industry continues to be highly vulnerable to cyberattacks

Cybersecurity is a growing market in the medical devices sector for several reasons. Medical devices often collect and contain vulnerable data, such as patient medical information. Legacy medical devices are a cause for concern because they likely were not designed with cyberattacks in mind. With the adoption of EHR systems, telemedicine measures, mobile health apps, and other connected devices, there is increased vulnerability to cyberattacks.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close